Redução de custos

Abordagem sistemática e multimodal

Impact of a patient blood management monitoring and feedback programme on allogeneic blood transfusions and related costs. (abre uma nova janela)

Kaserer A, Rössler J, Braun J, Farokhzad F, Pape HC, Dutkowski P, Plass A, Horisberger T, Volbracht J, Manz MG, Spahn, DR

Fonte‎: Anaesthesia 2019;74(12):1534-41.

Indexado‎: PubMed 31448406

DOI‎: 10.1111/anae.14816

https://www.ncbi.nlm.nih.gov/pubmed/31448406 (abre uma nova janela)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (abre uma nova janela)

Kaur MN, Arnold DM, Heddle NM, Cook RJ, Hsia C, Blostein M, Jamula E, Sholzberg M, Lin Y, Kassis J, Larratt L, Tinmouth A, Carruthers J, Li N, Liu Y, Xie F

Fonte‎: Blood Adv. 2022;6(3):785-92.

Indexado‎: PubMed 34781363

DOI‎: 10.1182/bloodadvances.2021005627

https://pubmed.ncbi.nlm.nih.gov/34781363/ (abre uma nova janela)

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (abre uma nova janela)

Leahy MF, Trentino KM, May C, Swain SG, Chuah H, Farmer SL.

Fonte‎: Transfusion 2017;57(9):2189-96.

Indexado‎: PubMed 28671296

DOI‎: 10.1111/trf.14191

https://www.ncbi.nlm.nih.gov/pubmed/28671296 (abre uma nova janela)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (abre uma nova janela)

Mehra T, Seifert B, Bravo-Reiter S, Wanner G, Dutkowski P, Holubec T, Moos RM, Volbracht J, Manz MG, Spahn DR

Fonte‎: Transfusion 2015;55(12):2807-15.

Indexado‎: PubMed 26264557

DOI‎: 10.1111/trf.13260

https://www.ncbi.nlm.nih.gov/pubmed/26264557 (abre uma nova janela)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (abre uma nova janela)

Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C.

Fonte‎: Transfusion 2010;50(2):487-92.

Indexado‎: PubMed 19804569

DOI‎: 10.1111/j.1537-2995.2009.02413.x

https://www.ncbi.nlm.nih.gov/pubmed/19804569 (abre uma nova janela)

Anemia Management

Should intravenous iron be the standard of care in oncology? (abre uma nova janela)

Auerbach M.

Fonte‎: J Clin Oncol 2008;26(10):1579-81.

Indexado‎: PubMed 18375888

DOI‎: 10.1200/JCO.2007.15.4609

https://www.ncbi.nlm.nih.gov/pubmed/18375888 (abre uma nova janela)

Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (abre uma nova janela)

Beverina I, Razionale G, Ranzini M, Aloni A, Finazzi S, Brando B.

Fonte‎: Blood Transfus 2020;18(2):106-16.

Indexado‎: PubMed 31855149

DOI‎: 10.2450/2019.0248-19

https://www.ncbi.nlm.nih.gov/pubmed/31855149 (abre uma nova janela)

The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model. (abre uma nova janela)

Borg S, Glenngård AH, Osterborg A, Persson U.

Fonte‎: Acta Oncol 2008;47(6):1009-17.

Indexado‎: PubMed 18770060

DOI‎: 10.1080/02841860701744498

https://www.ncbi.nlm.nih.gov/pubmed/18770060 (abre uma nova janela)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (abre uma nova janela)

Deger M, Eisterer W, Kutikova L, Salek S.

Fonte‎: Support Care Cancer 2013;21(2):485-93.

Indexado‎: PubMed 22825456

DOI‎: 10.1007/s00520-012-1538-0

https://www.ncbi.nlm.nih.gov/pubmed/22825456 (abre uma nova janela)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (abre uma nova janela)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Fonte‎: Cancer 2013;119(1):107-14.

Indexado‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (abre uma nova janela)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (abre uma nova janela)

Nikolaidi E, Hatzikou M, Geitona M.

Fonte‎: Cost Eff Resour Alloc 2013;11(1):16.

Indexado‎: PubMed 23870502

DOI‎: 10.1186/1478-7547-11-16

https://www.ncbi.nlm.nih.gov/pubmed/23870502 (abre uma nova janela)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (abre uma nova janela)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Fonte‎: Support Care Cancer 2012;20(1):159-65.

Indexado‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (abre uma nova janela)

Agentes hemostáticos

Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (abre uma nova janela)

Guest JF, Watson HG, Limaye S.

Fonte‎: Clin Ther 2010;32(14):2478-93.

Indexado‎: PubMed 21353116

DOI‎: 10.1016/j.clinthera.2011.01.011

https://www.ncbi.nlm.nih.gov/pubmed/21353116 (abre uma nova janela)

Recombinant activated factor VII use in critically ill infants with active hemorrhage. (abre uma nova janela)

Jen H, Shew S.

Fonte‎: J Pediatr Surg 2008;43(12):2235-8.

Indexado‎: PubMed 19040942

DOI‎: 10.1016/j.jpedsurg.2008.08.053

https://www.ncbi.nlm.nih.gov/pubmed/19040942 (abre uma nova janela)

Gestão e conservação de sangue periprocedimento/intraoperatório

Restrictive blood transfusion practices are associated with improved patient outcomes. (abre uma nova janela)

Goodnough LT, Maggio P, Hadhazy E, Shieh L, Hernandez-Boussard T, Khari P, Shah N.

Fonte‎: Transfusion 2014;54(10 Pt 2):2753-9.

Indexado‎: PubMed 24995770

DOI‎: 10.1111/trf.12723

https://www.ncbi.nlm.nih.gov/pubmed/24995770 (abre uma nova janela)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (abre uma nova janela)

Ravangard R, Mirzaei Z, Keshavarz K, Haghpanah S, Karimi M.

Fonte‎: Hematology 2018;23(7):417-22.

Indexado‎: PubMed 29157136

DOI‎: 10.1080/10245332.2017.1404262

https://www.ncbi.nlm.nih.gov/pubmed/29157136 (abre uma nova janela)

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (abre uma nova janela)

Stallworth JR, Jerrell JM, Tripathi A.

Fonte‎: Am J Hematol 2010;85(10):795-7.

Indexado‎: PubMed 20645429

DOI‎: 10.1002/ajh.21772

https://www.ncbi.nlm.nih.gov/pubmed/20645429 (abre uma nova janela)

HEMATOLOGIA E ONCOLOGIA

Redução de custos

Português (Portugal)

Redução de custos

/assets/ct/fa66d95d54/images/syn_placeholder_sqr.png

Abordagem sistemática e multimodal

Impact of a patient blood management monitoring and feedback programme on allogeneic blood transfusions and related costs. (abre uma nova janela)

Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia. (abre uma nova janela)

Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. (abre uma nova janela)

Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (abre uma nova janela)

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. (abre uma nova janela)

Anemia Management

Should intravenous iron be the standard of care in oncology? (abre uma nova janela)

Early intravenous iron administration in the Emergency Department reduces red blood cell unit transfusion, hospitalisation, re-transfusion, length of stay and costs. (abre uma nova janela)

The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model. (abre uma nova janela)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. (abre uma nova janela)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (abre uma nova janela)

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece. (abre uma nova janela)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (abre uma nova janela)

Agentes hemostáticos

Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom. (abre uma nova janela)

Recombinant activated factor VII use in critically ill infants with active hemorrhage. (abre uma nova janela)

Gestão e conservação de sangue periprocedimento/intraoperatório

Restrictive blood transfusion practices are associated with improved patient outcomes. (abre uma nova janela)

Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study. (abre uma nova janela)

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. (abre uma nova janela)

Comissão de Ligação Hospitalar (CLH)

Dossiers de informação médica

Vídeos

Redução de custos

Abordagem sistemática e multimodal

Anemia Management

Agentes hemostáticos

Gestão e conservação de sangue periprocedimento/intraoperatório

Selecione a sua língua